MHRA-101198-PIP01-23-M01 (update)

Key Facts

Active Substance
Active Substance:
  • RISANKIZUMAB
Invented Name
  • Skyrizi
  • Skyrizi
  • Skyrizi
  • Skyrizi
  • Skyrizi
  • Skyrizi
  • Skyrizi
  • Skyrizi
  • Skyrizi
  • Skyrizi
PIP Number MHRA-101198-PIP01-23-M01 (update)
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Concentrate for solution for infusion Solution for injection Age-appropriate dosage form for parenteral use
Therapeutic area
Therapeutic area:
  • Gastroenterology-Hepatology
Conditions / Indications
Conditions / Indications:
  • Treatment of Crohn's disease
Route(s) of administration
Route(s) of administration:
  • INTRAVENOUS USE SUBCUTANEOUS USE
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):RISANKIZUMAB.pdf
Published Date 24/06/2024